{"context":{"query":">>mondo>>clinical_trials","source_dataset":"mondo","target_dataset":"clinical_trials"},"stats":{"queried":1,"total":100,"mapped":1},"pagination":{"has_next":true,"next_token":"-1[]MONDO:0013209,73,MONDO:0013209,63,0]["},"schema":"id|brief_title|overall_status|phase|study_type","mappings":[{"input":"MONDO:0013209","source":"MONDO:0013209|metabolic dysfunction-associated steatotic liver disease","targets":["NCT00760513|Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids|COMPLETED|PHASE4|INTERVENTIONAL","NCT00941642|Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease|UNKNOWN|PHASE4|INTERVENTIONAL","NCT00994682|University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)|COMPLETED|PHASE4|INTERVENTIONAL","NCT01006889|Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT01208649|Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)|COMPLETED|PHASE4|INTERVENTIONAL","NCT01355575|Rifaximin in Fatty Liver Disease|TERMINATED|PHASE4|INTERVENTIONAL","NCT02051842|Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis|UNKNOWN|PHASE4|INTERVENTIONAL","NCT02147925|Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects|COMPLETED|PHASE4|INTERVENTIONAL","NCT02213224|Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease|UNKNOWN|PHASE4|INTERVENTIONAL","NCT02263677|Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT02285205|A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD|COMPLETED|PHASE4|INTERVENTIONAL","NCT02303730|Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes|COMPLETED|PHASE4|INTERVENTIONAL","NCT02329405|The Effects of PXR Activation on Hepatic Fat Content|COMPLETED|PHASE4|INTERVENTIONAL","NCT02500147|Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)|TERMINATED|PHASE4|INTERVENTIONAL","NCT02637973|Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes|COMPLETED|PHASE4|INTERVENTIONAL","NCT02649465|SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD|COMPLETED|PHASE4|INTERVENTIONAL","NCT02964715|The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes|UNKNOWN|PHASE4|INTERVENTIONAL","NCT02973295|Silymarin in NAFLD|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT03068065|Antidiabetic Effects on Intrahepatic Fat|COMPLETED|PHASE4|INTERVENTIONAL","NCT03434613|Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT03444233|Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women.|COMPLETED|PHASE4|INTERVENTIONAL","NCT03646292|Antidiabetic Drugs for Steatotic Liver Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT03796975|Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT03849729|Effectiveness and Tolerability of Phentermine in Patients Under Bariatric Surgery|COMPLETED|PHASE4|INTERVENTIONAL","NCT03910361|Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases|COMPLETED|PHASE4|INTERVENTIONAL","NCT04038853|Vitamin D in Fatty Liver Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT04248335|Effect of Obesity on Proton Pump Inhibitors|COMPLETED|PHASE4|INTERVENTIONAL","NCT04465032|The Effect of Consecutive Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease (NAFLD)|UNKNOWN|PHASE4|INTERVENTIONAL","NCT04475276|Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases|COMPLETED|PHASE4|INTERVENTIONAL","NCT04639414|Combined Active Treatment in Type 2 Diabetes with NASH|ACTIVE_NOT_RECRUITING|PHASE4|INTERVENTIONAL","NCT04642261|Effect of Empagliflozin on Liver Fat in Non-diabetic Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT04910178|Follow-up of NAFLD Patients With MRI-PDFF|COMPLETED|PHASE4|INTERVENTIONAL","NCT04976283|Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver|UNKNOWN|PHASE4|INTERVENTIONAL","NCT05042245|The Efficacy and Safety of Ornithine Aspartic Acid Granules in NAFLD Against Silymarin Capsules|UNKNOWN|PHASE4|INTERVENTIONAL","NCT05147090|Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients|ACTIVE_NOT_RECRUITING|PHASE4|INTERVENTIONAL","NCT05195944|Semaglutide vs Sitagliptin|UNKNOWN|PHASE4|INTERVENTIONAL","NCT05305287|Quantifying Hepatic Mitochondrial Fluxes in Humans|RECRUITING|PHASE4|INTERVENTIONAL","NCT05459701|Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)|COMPLETED|PHASE4|INTERVENTIONAL","NCT05474560|Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT05647915|Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals with Obesity and NAFLD|COMPLETED|PHASE4|INTERVENTIONAL","NCT05813249|Semaglutide in Nonalcoholic Fatty Liver Disease|COMPLETED|PHASE4|INTERVENTIONAL","NCT05872269|A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities|RECRUITING|PHASE4|INTERVENTIONAL","NCT05942963|Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD|UNKNOWN|PHASE4|INTERVENTIONAL","NCT06060886|Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis|UNKNOWN|PHASE4|INTERVENTIONAL","NCT06074094|Probiotic Supplementation IN NAFLD Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT06218342|Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease|UNKNOWN|PHASE4|INTERVENTIONAL","NCT06256289|Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome|NOT_YET_RECRUITING|PHASE4|INTERVENTIONAL","NCT06368882|Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT）|RECRUITING|PHASE4|INTERVENTIONAL","NCT06374875|Fibrosis Lessens After Metabolic Surgery|RECRUITING|PHASE4|INTERVENTIONAL","NCT06449833|Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD|RECRUITING|PHASE4|INTERVENTIONAL","NCT06501326|Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease|UNKNOWN|PHASE4|INTERVENTIONAL","NCT06523530|Effect of a GnRH Analog on Hepatic Steatosis|RECRUITING|PHASE4|INTERVENTIONAL","NCT06762223|Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM|NOT_YET_RECRUITING|PHASE4|INTERVENTIONAL","NCT06845345|Effect of Mediterranean Diet Combined With Intermittent Fasting on Liver Fibrosis Compared to Naltrexone/Bupropion in People With Cardiometabolic Risk Factors (MEDFAST-study)|ENROLLING_BY_INVITATION|PHASE4|INTERVENTIONAL","NCT06920316|Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)|NOT_YET_RECRUITING|PHASE4|INTERVENTIONAL","NCT07071636|Clinical Efficacy of Pegylated Interferon Alpha-2b Combined With Nucleos(t)Ide Analogues in the Treatment of Chronic Hepatitis B Patients|NOT_YET_RECRUITING|PHASE4|INTERVENTIONAL","NCT07274644|Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease|ENROLLING_BY_INVITATION|PHASE4|INTERVENTIONAL","NCT07363707|A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes.|COMPLETED|PHASE4|INTERVENTIONAL","NCT00650546|Role of Exenatide in NASH-a Pilot Study|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00658164|Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores|UNKNOWN|PHASE3|INTERVENTIONAL","NCT01418027|Combined Intensive and Conventional Exercise on Nonalcoholic Fatty Liver Disease (NAFLD)|COMPLETED|PHASE3|INTERVENTIONAL","NCT01529268|Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT01934777|Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis|COMPLETED|PHASE3|INTERVENTIONAL","NCT02098317|DHA and Vitamin D in Children With Biopsy-proven NAFLD|COMPLETED|PHASE3|INTERVENTIONAL","NCT02132442|Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes|COMPLETED|PHASE3|INTERVENTIONAL","NCT02216552|Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT02242149|Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects|COMPLETED|PHASE3|INTERVENTIONAL","NCT02303314|Efficacy of Oral Trigonella Foenum-graecum Seed Extract Vs Placebo in Treatment of None Alcoholic Fatty Liver Disease|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT02535195|Effect of Ginger Supplement on Non-alcoholic Fatty Liver|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT02654665|Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults|UNKNOWN|PHASE3|INTERVENTIONAL","NCT02842567|Hydroxytyrosol and Vitamin E in Pediatric NASH|COMPLETED|PHASE3|INTERVENTIONAL","NCT03585413|Impact of a Specific Micronutrient-probiotic-supplement on Fatty Liver of Patients After Mini-Gastric Bypass Surgery|COMPLETED|PHASE3|INTERVENTIONAL","NCT03919929|Treating PCOS With Semaglutide vs Active Lifestyle Intervention|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT03970031|A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH|UNKNOWN|PHASE3|INTERVENTIONAL","NCT04142749|Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis|COMPLETED|PHASE3|INTERVENTIONAL","NCT04193982|An Investigator Initiated Prospective, Four Arms Randomized Comparative Study of Efficacy and Safety of Saroglitazar, Vitamin E and Life Style Modification in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH)|UNKNOWN|PHASE3|INTERVENTIONAL","NCT04197479|A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients|COMPLETED|PHASE3|INTERVENTIONAL","NCT04237116|A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)|TERMINATED|PHASE3|INTERVENTIONAL","NCT04308980|Safety and Tolerability of Novel Medical Nutrition Products for NAFLD Treatment|UNKNOWN|PHASE2/PHASE3|INTERVENTIONAL","NCT04411862|Efficacy of Phosphatidylcholine in NAFLD|COMPLETED|PHASE3|INTERVENTIONAL","NCT04756544|The Influence of Probiotic Supplementation on Depressive Symptoms, Inflammation and Oxidative Stress Parameters and Faecal Microbiota in Patients With Depression Depending on Metabolic Syndrome Comorbidity|UNKNOWN|PHASE3|INTERVENTIONAL","NCT04951219|A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT05521633|Comparison of the Effects of Metformin and Pioglitazone on Liver Enzymes and Ultrasound Changes in Non-Diabetic Non-Alcoholic Fatty Liver|COMPLETED|PHASE3|INTERVENTIONAL","NCT05613192|Effectiveness of Inactive Vitamin D Supplementation in Non-Alcoholic Fatty Liver Disease Patients|UNKNOWN|PHASE3|INTERVENTIONAL","NCT05768334|Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease|COMPLETED|PHASE3|INTERVENTIONAL","NCT05935826|Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)|RECRUITING|PHASE3|INTERVENTIONAL","NCT06152991|Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy|ENROLLING_BY_INVITATION|PHASE3|INTERVENTIONAL","NCT06161571|A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT06692283|A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH|WITHDRAWN|PHASE3|INTERVENTIONAL","NCT07165028|A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)|RECRUITING|PHASE3|INTERVENTIONAL","NCT07221188|A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH|RECRUITING|PHASE3|INTERVENTIONAL","NCT07221227|A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH|RECRUITING|PHASE3|INTERVENTIONAL","NCT00230087|Iron Depletion Therapy for Type 2 DM and NAFLD|COMPLETED|PHASE2|INTERVENTIONAL","NCT00230113|Effect of Omega-3 PUFA Supplementation in NAFLD Patients|COMPLETED|PHASE2|INTERVENTIONAL","NCT00596934|Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)|COMPLETED|PHASE2|INTERVENTIONAL","NCT00633282|Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease|COMPLETED|PHASE2|INTERVENTIONAL","NCT00677521|A Pilot Study of Acarbose as Treatment for Pediatric Non-alcoholic Fatty Liver Disease (NAFLD)|TERMINATED|PHASE2|INTERVENTIONAL","NCT00699036|Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH)|UNKNOWN|PHASE2|INTERVENTIONAL","NCT00794716|PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)|COMPLETED|PHASE2|INTERVENTIONAL","NCT00819338|The Effect of n-3 Polyunsaturated Fatty Acid Supplements in Patients With Non-alcoholic Fatty Liver Disease|COMPLETED|PHASE2|INTERVENTIONAL"]}]}